![](/img/cover-not-exists.png)
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
Robertson, Kevin, Maruff, Paul, Ross, Lisa L., Wohl, David, Small, Catherine B, Edelstein, Howard, Shaefer, Mark S.Language:
english
Journal:
Journal of NeuroVirology
DOI:
10.1007/s13365-018-0680-y
Date:
October, 2018
File:
PDF, 470 KB
english, 2018